Partnership will improve care for pancreatic cancer patients
myTomorrows, a global health technology company connecting patients with the full range of treatment options, has announced a new collaboration with Pancreatic Cancer Europe, a multi-stakeholder platform bringing together experts from across Europe to improve care for patients with pancreatic cancer.
Through the new partnership, Pancreatic Cancer Europe (PCE) will leverage myTomorrows’ database of ongoing clinical trials to provide patients, carers and healthcare professionals (HCPs) with up-to-date, accessible information on pre-approved treatments that may be relevant to them.
The partnership with European patient advocacy groups and myTomorrows will help ensure that patients suffering from a range of life-threatening diseases have access to the full range of treatment options. For pancreatic cancer patients and healthcare professionals, the partnership will help ease the process of identifying and understanding existing clinical trial options.
Pancreatic cancer is the fourth leading cause of cancer deaths, with an average life expectancy at diagnosis of just 6-12 months and a five-year survival rate of just 10%. Many challenges associated with pancreatic cancer include a lack of awareness of the disease among the general public, delayed diagnosis, resistance to chemotherapy and radiotherapy, low survival rates, and limited treatment options. It is therefore important that patients are informed as accurately and thoroughly as possible about their treatment options, especially clinical trials, which can often be difficult to find, understand, and navigate.
